Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 28	DEC 18	CA/CAplus patent kind codes updated
NEWS 29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 30	DEC 18	MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)
H-FABP IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)
2712469 H
2568 FABP
259 FABPS
2580 FABP
(FABP OR FABPS)
319 H-FABP
(H(W)FABP)
93 HFABP
1 HFABPS
93 HFABP
(HFABP OR HFABPS)
2712469 H
2568 FABP

```
          259 FABPS
         2580 FABP
                (FABP OR FABPS)
          319 H (W) FABP
       335556 HEART
        28346 HEARTS
       337380 HEART
                (HEART OR HEARTS)
      1745637 TYPE
       598781 TYPES
      2208661 TYPE
                (TYPE OR TYPES)
       373756 FATTY
           14 FATTIES
       373760 FATTY
                (FATTY OR FATTIES)
      4259872 ACID
      1553426 ACIDS
      4757683 ACID
                (ACID OR ACIDS)
       953897 BINDING
         2080 BINDINGS
       954489 BINDING
                (BINDING OR BINDINGS)
      1948078 PROTEIN
      1364406 PROTEINS
      2269874 PROTEIN
                (PROTEIN OR PROTEINS)
          128 HEART-TYPE FATTY ACID BINDING PROTEIN
                (HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)
       335556 HEART
        28346 HEARTS
       337380 HEART
                (HEART OR HEARTS)
      1745637 TYPE
       598781 TYPES
      2208661 TYPE
                (TYPE OR TYPES)
            1 FACTTY
      4259872 ACID
      1553426 ACIDS
      4757683 ACID
                (ACID OR ACIDS)
            0 HEART TYPE FACTTY ACID
                (HEART(W)TYPE(W)FACTTY(W)ACID)
       953897 BINDING
         2080 BINDINGS
       954489 BINDING
                (BINDING OR BINDINGS)
      1948078 PROTEIN
      1364406 PROTEINS
      2269874 PROTEIN
                (PROTEIN OR PROTEINS)
       154312 BINDING PROTEIN
                (BINDING(W)PROTEIN)
            0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L1          380 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
                BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s doxorubicin or adriamycin
          15810 DOXORUBICIN
             28 DOXORUBICINS
          15812 DOXORUBICIN
                (DOXORUBICIN OR DOXORUBICINS)
          10770 ADRIAMYCIN
```

```
          16 ADRIAMYCINS
       10772 ADRIAMYCIN
                (ADRIAMYCIN OR ADRIAMYCINS)
L2     25686 DOXORUBICIN OR ADRIAMYCIN

=> a l2 and l1
A IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and l1
L3          2 L2 AND L1

=> d ibib

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:450309  CAPLUS
DOCUMENT NUMBER:          141:36901
TITLE:                    Limited role of N-terminal phosphoserine residues in
                          the activation of transcription by p53
AUTHOR(S):                Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna
                          L.; Agarwal, Archana; Stanhope-Baker, Patricia;
                          Williams, Bryan R. G.; Stark, George R.
CORPORATE SOURCE:         Department of Molecular Biology, Lerner Research
                          Institute, Cleveland Clinic Foundation, Cleveland, OH,
                          44195, USA
SOURCE:                   Oncogene (2004), 23(25), 4477-4487
                          CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER:                Nature Publishing Group
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          87    THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib 1-2

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:450309  CAPLUS
DOCUMENT NUMBER:          141:36901
TITLE:                    Limited role of N-terminal phosphoserine residues in
                          the activation of transcription by p53
AUTHOR(S):                Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna
                          L.; Agarwal, Archana; Stanhope-Baker, Patricia;
                          Williams, Bryan R. G.; Stark, George R.
CORPORATE SOURCE:         Department of Molecular Biology, Lerner Research
                          Institute, Cleveland Clinic Foundation, Cleveland, OH,
                          44195, USA
SOURCE:                   Oncogene (2004), 23(25), 4477-4487
                          CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER:                Nature Publishing Group
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
REFERENCE COUNT:          87    THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:797013  CAPLUS
DOCUMENT NUMBER:          139:286301
TITLE:                    Method of judging cardiotoxicity of anthracycline-type
                          anticancer chemical therapeutic by detecting human
                          H-FABP and reagent therefor
INVENTOR(S):              Kitayama, Hitoshi; Ohkaru, Yasuhiko
PATENT ASSIGNEE(S):       Dainippon Pharmaceutical Co., Ltd., Japan
```

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003083486	A1	20031009	WO 2003-JP3924	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003220882	A1	20031013	AU 2003-220882	20030328
EP 1491896	A1	20041229	EP 2003-715565	20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005202513	A1	20050915	US 2004-509571	20040929
PRIORITY APPLN. INFO.:			JP 2002-93688 A	20020329
			WO 2003-JP3924 W	20030328

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s cancer? or tumor? or neoplas?
        315544 CANCER?
        452001 TUMOR?
        474391 NEOPLAS?
L4      748872 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 and l1
L5          32 L4 AND L1

=> s l5 not py>2002
       4707679 PY>2002
L6          8 L5 NOT PY>2002

=> s l6 and antibod?
        479076 ANTIBOD?
L7          2 L6 AND ANTIBOD?

=> d ibib 1-2

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2000:376177  CAPLUS
DOCUMENT NUMBER:        133:248010
TITLE:                  Identification of differentially expressed genes in
                        cardiac hypertrophy by analysis of expressed sequence
                        tags
AUTHOR(S):              Hwang, David M.; Dempsey, Adam A.; Lee, Cheuk-Yu;
                        Liew, Choong-Chin
CORPORATE SOURCE:       Cardiac Gene Unit, Department of Laboratory Medicine
                        and Pathobiology, Centre for Cardiovascular Research,
                        Toronto Hospital, University of Toronto, Toronto, ON,
                        M5G 1L5, Can.
SOURCE:                 Genomics (2000), 66(1), 1-14
                        CODEN: GNMCEP; ISSN: 0888-7543
PUBLISHER:              Academic Press
```

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:682528 CAPLUS
DOCUMENT NUMBER: 129:299045
TITLE: Cloning and cDNA sequence of human fatty acid-binding protein
INVENTOR(S): Hillman, Jennifer L.; Shah, Purvi
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845440	A1	19981015	WO 1998-US7084	19980408
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868942	A	19981030	AU 1998-68942	19980408
PRIORITY APPLN. INFO.:			US 1997-825783	A2 19970408
			WO 1998-US7084	W 19980408

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . polynucleotides which identify and encode Hu-FABP. Nucleic acids encoding Hu-FABP were first identified in Incyte clone 2581906 from a kidney tumor tissue cDNA library through a computer-generated search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or. . . acids in length and chemical and structural homol. with FABP from chick retina, B-FABP from rat and mouse brain, and H-FABP from mouse and human heart.
Northern anal. shows the most abundant expression of Hu-FABP in fetal brain, which suggests a developmental role for this mol. In adults, Hu-FABP is found primarily in cancer-associated tissues, particularly, brain, kidney, and breast. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-FABP, as. . .
IT Antibodies
Probes (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cloning and cDNA sequence of human fatty acid-binding protein)

=> file pctfull
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 59.03 59.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION

```
CA SUBSCRIBER PRICE                                    -0.75       -0.75

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:          19 DEC 2006      <20061219/UP>
MOST RECENT UPDATE WEEK:        200650        <200650/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or
(heart type factty acid () binding protein)
        485934 H
           291 FABP
            51 FABPS
           307 FABP
                 (FABP OR FABPS)
            45 H-FABP
                 (H(W)FABP)
             8 HFABP
        485934 H
           291 FABP
            51 FABPS
           307 FABP
                 (FABP OR FABPS)
            45 H (W) FABP
         64305 HEART
          4368 HEARTS
         65049 HEART
                 (HEART OR HEARTS)
        651740 TYPE
        384590 TYPES
        710359 TYPE
                 (TYPE OR TYPES)
         75579 FATTY
             2 FATTIES
         75580 FATTY
                 (FATTY OR FATTIES)
        286591 ACID
        191691 ACIDS
        297259 ACID
                 (ACID OR ACIDS)
        138670 BINDING
          2428 BINDINGS
        139156 BINDING
                 (BINDING OR BINDINGS)
        144350 PROTEIN
        122052 PROTEINS
        159658 PROTEIN
                 (PROTEIN OR PROTEINS)
            18 HEART-TYPE FATTY ACID BINDING PROTEIN
                 (HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)
         64305 HEART
          4368 HEARTS
         65049 HEART
                 (HEART OR HEARTS)
        651740 TYPE
```

```
        384590 TYPES
        710359 TYPE
                 (TYPE OR TYPES)
             0 FACTTY
        286591 ACID
        191691 ACIDS
        297259 ACID
                 (ACID OR ACIDS)
             0 HEART TYPE FACTTY ACID
                 (HEART(W)TYPE(W)FACTTY(W)ACID)
        138670 BINDING
          2428 BINDINGS
        139156 BINDING
                 (BINDING OR BINDINGS)
        144350 PROTEIN
        122052 PROTEINS
        159658 PROTEIN
                 (PROTEIN OR PROTEINS)
         31430 BINDING PROTEIN
                 (BINDING(W)PROTEIN)
             0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L8          57 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
               BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s l8 and antibod?
         93871 ANTIBOD?
L9          41 L8 AND ANTIBOD?

=> s l9 and doxorucicin or daunomycin or anthracyclin?
             1 DOXORUCICIN
          3555 DAUNOMYCIN
            22 DAUNOMYCINS
          3565 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
          4401 ANTHRACYCLIN?
L10       6166 L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

=> s l9 and (doxorucicin or daunomycin or anthracyclin?)
             1 DOXORUCICIN
          3555 DAUNOMYCIN
            22 DAUNOMYCINS
          3565 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
          4401 ANTHRACYCLIN?
L11          2 L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> d ibib 1-2

L11    ANSWER 1 OF 2     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2006131928 PCTFULL  ED 20061219  EW 200650
TITLE (ENGLISH):         NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS
                         AND METHODS OF USE THEREOF FOR DIAGNOSIS
TITLE (FRENCH):          NOUVELLES SEQUENCES DE NUCLEOTIDES ET D'ACIDES AMINES,
                         LEURS DOSAGES ET METHODES D'UTILISATION EN VUE DU
                         DIAGNOSTIC
INVENTOR(S):             SAMEAH-GREENWALD, Shirley, 33/7 Arlozorov Street, 44453
                         Kfar-saba, IL;
                         NOVIK, Amit, 31 Hasayfan Street, 40600 Tel-mond, IL;
                         WALLACH, Shira, 40 Bnei Brit Street, 45265
                         Hod-hasharon, IL;
                         POLLOCK, Sarah, 16/2 Hoshea Street, 63506 Tel-aviv, IL;
                         BAZAK, Lily, 46 Raynes Street, 53461 Givatayim, IL;
                         TSYPKIN, Elena, 105/7 Even Gvirol Street, 64046
                         Tel-aviv, IL;
                         COJOCARU, Gad, S., 41/7 Hasayfan Street, 47248
```

Ramat-hasharon, IL;
SELLA-TAVOR, Osnat, 18 Kfar Kish, 19330 Kfar Kish, IL

PATENT ASSIGNEE(S): COMPUGEN LTD., 72 Pinchas Rosen Street, 69512 Tel Aviv, IL

AGENT: WEBB, Cynthia et al.$, Webb & Associates, P.O. Box 2189, 76121 Rehovot$, IL

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2006131928	A2	20061214

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2006-IL676 A 20060608

PRIORITY INFO.: US 2005-60688320 20050608
US 2005-60699427 20050715
US 2005-60704414 20050802

L11 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 2006026785 PCTFULL ED 20060403 EW 200610

TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR MODULATING PGC-1a TO TREAT NEUROLOGICAL DISEASES AND DISORDERS

TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE MODULATION DE PGC-1$G(A) POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES NEUROLOGIQUES

INVENTOR(S): LIN, Jiandie, 79 Chestnut Street, Apt.#1, Brookline, MA 02445, US;
SPIEGELMAN, Bruce, M., 271 Waban Avenue, Waban, MA 02168, US

PATENT ASSIGNEE(S): DANA-FARBER CANCER INSTITUTE, INC., 44 Binney Street, Boston, MA 02115-6084, US

AGENT: SMITH, DeAnn, F. et al.$, Patent Group, Foley Hoag LLP, Seaport World Trade Center West, 155 Seaport Blvd., Boston, MA 02210; 02210$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2006026785	A2	20060309

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

```
APPLICATION INFO.:      WO 2005-US31715      A  20050906
PRIORITY INFO.:         US 2004-60607412        20040903


=> d his

     (FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

     FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
L1           380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2         25686 S DOXORUBICIN OR ADRIAMYCIN
L3             2 S L2 AND L1
L4        748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5            32 S L4 AND L1
L6             8 S L5 NOT PY>2002
L7             2 S L6 AND ANTIBOD?

     FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
L8            57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9            41 S L8 AND ANTIBOD?'
L10         6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11           2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> s l9 not py>2002
        481204 PY>2002
L12          12 L9 NOT PY>2002

=> s l12 and kit
          81427 KIT
          38881 KITS
          87623 KIT
                (KIT OR KITS)
L13           9 L12 AND KIT

=> s l8/ab
          16209 H/AB
             16 FABP/AB
              1 FABPS/AB
             17 FABP/AB
                ((FABP OR FABPS)/AB)
              6 H-FABP/AB
                ((H(W)FABP)/AB)
              0 HFABP/AB
          16209 H/AB
             16 FABP/AB
              1 FABPS/AB
             17 FABP/AB
                ((FABP OR FABPS)/AB)
              6 H/AB (W) FABP/AB
           5057 HEART/AB
             33 HEARTS/AB
           5073 HEART/AB
                ((HEART OR HEARTS)/AB)
          87567 TYPE/AB
          15286 TYPES/AB
          98263 TYPE/AB
                ((TYPE OR TYPES)/AB)
           6744 FATTY/AB
          63647 ACID/AB
          17172 ACIDS/AB
          73135 ACID/AB
                ((ACID OR ACIDS)/AB)
          16377 BINDING/AB
            141 BINDINGS/AB
          16461 BINDING/AB
```

```
              ((BINDING OR BINDINGS)/AB)
         25316 PROTEIN/AB
         14190 PROTEINS/AB
         34108 PROTEIN/AB
               ((PROTEIN OR PROTEINS)/AB)
             0 HEART-TYPE FATTY ACID BINDING PROTEIN/AB
               ((HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)/AB)
          5057 HEART/AB
            33 HEARTS/AB
          5073 HEART/AB
               ((HEART OR HEARTS)/AB)
         87567 TYPE/AB
         15286 TYPES/AB
         98263 TYPE/AB
               ((TYPE OR TYPES)/AB)
             0 FACTTY/AB
         63647 ACID/AB
         17172 ACIDS/AB
         73135 ACID/AB
               ((ACID OR ACIDS)/AB)
             0 HEART TYPE FACTTY ACID/AB
               ((HEART(W)TYPE(W)FACTTY(W)ACID)/AB)
         16377 BINDING/AB
           141 BINDINGS/AB
         16461 BINDING/AB
               ((BINDING OR BINDINGS)/AB)
         25316 PROTEIN/AB
         14190 PROTEINS/AB
         34108 PROTEIN/AB
               ((PROTEIN OR PROTEINS)/AB)
          1255 BINDING PROTEIN/AB
               ((BINDING(W)PROTEIN)/AB)
             0 HEART TYPE FACTTY ACID/AB (W) BINDING PROTEIN/AB
L14          6 (H-FABP/AB OR (HFABP/AB) OR (H/AB (W) FABP/AB) OR (HEART-TYPE
               FATTY ACID BINDING PROTEIN/AB) OR (HEART TYPE FACTTY ACID/AB
              (W) BINDING PROTEIN/AB))

=> s l8/clm
        190960 H/CLM
            60 FABP/CLM
            14 H-FABP/CLM
               ((H(W)FABP)/CLM)
             1 HFABP/CLM
        190960 H/CLM
            60 FABP/CLM
            14 H/CLM (W) FABP/CLM
         11386 HEART/CLM
        104803 TYPE/CLM
         14215 FATTY/CLM
        136223 ACID/CLM
         40435 BINDING/CLM
         52853 PROTEIN/CLM
             6 HEART-TYPE FATTY ACID BINDING PROTEIN/CLM
               ((HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)/CLM)
         11386 HEART/CLM
        104803 TYPE/CLM
             0 FACTTY/CLM
        136223 ACID/CLM
             0 HEART TYPE FACTTY ACID/CLM
               ((HEART(W)TYPE(W)FACTTY(W)ACID)/CLM)
         40435 BINDING/CLM
         52853 PROTEIN/CLM
          3331 BINDING PROTEIN/CLM
               ((BINDING(W)PROTEIN)/CLM)
             0 HEART TYPE FACTTY ACID/CLM (W) BINDING PROTEIN/CLM
```

```
L15          17 (H-FABP/CLM OR (HFABP/CLM) OR (H/CLM (W) FABP/CLM) OR (HEART-TYP
                E FATTY ACID BINDING PROTEIN/CLM) OR (HEART TYPE FACTTY ACID/CLM
                (W) BINDING PROTEIN/CLM))

=> s l15 or l14
L16          19 L15 OR L14

=> d his

     (FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

     FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
L1          380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2        25686 S DOXORUBICIN OR ADRIAMYCIN
L3            2 S L2 AND L1
L4       748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5           32 S L4 AND L1
L6            8 S L5 NOT PY>2002
L7            2 S L6 AND ANTIBOD?

     FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
L8           57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9           41 S L8 AND ANTIBOD?
L10        6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11           2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
L12          12 S L9 NOT PY>2002
L13           9 S L12 AND KIT
L14           6 S L8/AB
L15          17 S L8/CLM
L16          19 S L15 OR L14

=> s l16 and l13
L17           3 L16 AND L13

=> d ibib 1-3

L17    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2002089657 PCTFULL  ED 20021121  EW 200246
TITLE (ENGLISH):         DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND
                         METHODS OF USE THEREOF
TITLE (FRENCH):          MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS
                         ET LEURS METHODES D'UTILISATION
INVENTOR(S):             VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
                         92025, US [US, US];
                         DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego,
                         CA 92126, US [US, US];
                         KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
                         92121, US [US, US];
                         BUECHLER, Kenneth, F., 12523 Manifesto Place, San
                         Diego, CA 92130, US [US, US]
PATENT ASSIGNEE(S):      BIOSITE, INC., 11030 Roselle Street, San Diego, CA
                         92121, US [US, US], for all designates States except
                         US;
                         VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
                         92025, US [US, US], for US only;
                         DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego,
                         CA 92126, US [US, US], for US only;
                         KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
                         92121, US [US, US], for US only;
                         BUECHLER, Kenneth, F., 12523 Manifesto Place, San
                         Diego, CA 92130, US [US, US], for US only
AGENT:                   WARBURG, Richard, J.$, Foley & Lardner, P.O. Box 80278,
                         San Diego, CA 92138-0278$, US
LANGUAGE OF FILING:      English
LANGUAGE OF PUBL.:       English
```

DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002089657	A2	20021114

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US14219 A 20020504
PRIORITY INFO.: US 2001-60/288,871 20010504
US 2001-60/315,642 20010828

L17 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2001067108 PCTFULL
no bibliographic data available - please use FPI for PI information
DESIGNATED STATES

L17 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997035878 PCTFULL ED 20020514
TITLE (ENGLISH): THE PORCINE HEART FATTY ACID-BINDING PROTEIN ENCODING GENE AND METHODS TO IDENTIFY POLYMORPHISMS ASSOCIATED WITH BODY WEIGHT
TITLE (FRENCH): GENE CODANT UNE PROTEINE SE LIANT A UN ACIDE GRAS DU COEUR DE PORC ET PROCEDE D'IDENTIFICATION DES CARACTERISTIQUES DU POLYMORPHISME RESPONSABLES DU POIDS DU CORPS
INVENTOR(S): GERBENS, Frans
PATENT ASSIGNEE(S): DALLAND B.V.;
PROVA B.V.;
STAMBOEK ZUID B.V.;
NOORD NEDERLANDS VARKENSSTAMBOEK B.V.;
INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID (ID-DLO);
GERBENS, Frans
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735878	A2	19971002

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1997-NL157 A 19970327
PRIORITY INFO.: NL 1996-96200855.3 19960328

=> d ibib kwic 1

L17 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002089657 PCTFULL ED 20021121 EW 200246
TITLE (ENGLISH): DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND METHODS OF USE THEREOF

TITLE (FRENCH): MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS ET LEURS METHODES D'UTILISATION

INVENTOR(S): VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA 92025, US [US, US];
DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego, CA 92126, US [US, US];
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA 92121, US [US, US];
BUECHLER, Kenneth, F., 12523 Manifesto Place, San Diego, CA 92130, US [US, US]

PATENT ASSIGNEE(S): BIOSITE, INC., 11030 Roselle Street, San Diego, CA 92121, US [US, US], for all designates States except US;
VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA 92025, US [US, US], for US only;
DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego, CA 92126, US [US, US], for US only;
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA 92121, US [US, US], for US only;
BUECHLER, Kenneth, F., 12523 Manifesto Place, San Diego, CA 92130, US [US, US], for US only

AGENT: WARBURG, Richard, J.$, Foley & Lardner, P.O. Box 80278, San Diego, CA 92138-0278$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002089657	A2	20021114

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US14219 A 20020504
PRIORITY INFO.: US 2001-60/288,871 20010504
US 2001-60/315,642 20010828

DETD . . . annexin V, B-type natriuretic peptide, P-enolase, cardiac troponin I (free and/or complexed), cardiac troponin T (free and/or coinplexed), creatine kinase-MB, glycogen phosphorylase-BB, heart-type fatty acid binding protein, phosphoglyceric acid mutase-MB, and S-100ao. These specific markers are described in detail hereinafter.

[00381 In a further aspect, the invention relates to kits for determining the diagnosis or prognosis of a patient. These kits preferably comprise devices and reagents for measuring one or more marker levels in a patient sample, and instructions for performing the assay. Optionally, the kits may contain one or more means for converting marker level(s) to a prognosis. Such kits preferably contain sufficient

reagents to perform one or more such determinations.

al., Ain. J. Einerg. Med 17:225-229, 1999). This apparent non-specificity may be related to the quality and specificity of the antibodies used in the immunoassay. cTnI is released into the bloodstream following cardiac cell death. The plasma concentration of cTnI in patients with. . .

[00591 Heart-type fatty acid binding protein (H-FABP) is a cytosolic 15 kDa lipid-binding protein involved in lipid metabolism. Heart-type FABP antigen is found not only in heart tissue,. . . and Maatman, R.G., Prog. Lipid Res. 34:17-52,1995). The normal plasma concentration of FABP is < 6 ng/ml (400 pM). The plasma H-FABP concentration is elevated in patients with AMI and unstable angina (Ishii, J. et al., Clin. Chem. 43:1372-1378, 1997; Tsuji, R. et al., Int. J Cardiol. 41:209-217, 1993). Furthermore, H-FABP may be usefal in estimating infarct size in patients with AMI (Glatz, U. et al., Br.

Heart J. 71:13 5 -140, 1994). Myocardial tissue as a source of H -FABP can be confirmed by determining the ratio of myoglobin/FABP (grams/grams). A ratio of approximately 5 indicates that FABP is of myocardial origin,. . . while a higher ratio indicates skeletal muscle sources (Van Nieuwenhoven, F.A. et al., Circulation 92:2848-2854, 1995). Because of the presence of H-FABP in skeletal muscle, kidney and brain, elevations in the plasma H-FABP concentration may be associated with skeletal muscle injury, renal disease, or stroke. H-FABP is released into the bloodstream following cardiac tissue necrosis. The plasma H-FABP concentration can be significantly elevated 1-2 hours after the onset of chest pain, earlier than CK-MB and myoglobin (Tsuji, R. et al.,. . .

Additionally, H-FABP is rapidly cleared from the bloodstream, and plasma concentrations return to baseline after 24 hours after AMI onset (Glatz, J.F. et. . .

mediate crosslinking of platelets to vascular subendothelium, respectively. Measurement of any of these vWF forms, when used in an assay that employs antibodies specific for'the protease cleavage domain may allow assays to be used to determine the circulating concentration of various vWF forms in. . .

TpPTMmay also be useful in determining the severity of unstable angina. American Biogenetic Sciences, hic. instructs users of the TpPTm ELISA assay kit to collect blood using citrate as an anticoagulant, and they recommend against using EDTA. The effect of the anticoagulant used during. . .

in the art (for example, the measurement of marker RNA levels). The presence or amount of a marker is generally detennined using antibodies specific for each marker and detecting specific binding. Any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. Specific immunological binding of the antibody to the marker can be detected directly or indirectly. Direct labels include fluorescent or luminescent tags, metals, dyes, radionuclides, and the like, attached to the antibody. Indirect labels include various enzymes well known in the art, such as alkaline phosphatase, horseradish peroxidase and the like.

[00981 The use of immobilized antibodies specific for the markers is also contemplated by the present invention. The antibodies could be immobilized onto a variety of solid supports, such as magnetic or chromatographic matrix particles, the surface of an assay place. . . of a solid substrate material (such as plastic, nylon, paper), and the like. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip
55
could then be dipped into the test sample and then processed quickly through. . .

[01021 In another embodiment, the present invention provides a kit for the analysis of markers. Such a kit preferably comprises devises and reagents for the analysis of at least one test sample and instructions for perfonning the assay. Optionally the kits may contain one or more means for converting a marker level to a diagnosis or prognosis of I 0 the patient.

[01041 Markers were measured using standard immunoassay techniques. These techniques involved the use of antibodies to specifically bind the protein targets. A monoclonal antibody directed against a selected marker was biotinylated using N-hydroxysuccinimide biotin (NHS-biotin) at a ratio of about 5 NHS-biotin moieties per antibody. The antibody-biotin conjugate was then added to wells of a standard avidin 384 well microtiter plate, and antibody conjugate not bound to the plate was removed. This formed the anti-marker in the microtiter plate. Another monoclonal
57
antibody directed against the same marker was conjugated to alkaline phosphatase using succinimidyl 4-[N-maleimidomethyl]-cyclohexane- 1 -carboxylate (SMCC) and N-succinimidyl 3-[2-pyridyldithio]propionate (SPDP) (Pierce,. . .

[01051 Imrnunoassays were performed on a TECAN Genesis RSP 200/8 Workstation. Biotinylated antibodies were pipetted into microtiter plate wells previously coated with avidin and incubated for 60 min. The solution containing unbound antibody was removed, and the cells were washed with a wash buffer, consisting of 20 mM borate (pH 7.42) containing 15 0. . . wells, and incubated for 60 min. The sample was then removed and the wells were washed with a wash buffer. The antibody- alkaline phosphatase conjugate was then added to the wells and incubated for an additional 60 min, after which time, the antibody conjugate was removed and the wells were washed with a wash buffer. A substrate, (AttoPhos], Promega, Madison, WI) was added to. . .

[01061 Assays for BNP were performed using murine anti-BNP monoclonal antibody 106.3 obtained from Scios Incorporated (Sunnyvale, CA). The hybridoma cell line secreting mAb 106.3 was generated from a fusion between FOX-NY cells and spleen cells from a Balb/c mouse immunized with human BNP 1-32 conjugated to BSA. A second murine anti-BNP antibody was produced by Biosite Incorporated (San Diego, CA) by antibody phage display as described previously (US Patent No.

[01071 Assays for MMP-9 were performed using murine anti-MMP-9 antibodies generated by Biosite Incorporated using phage display and recombinant protein expression as described previously (`US Patent No '. 6,057,098). Commercially available M1\4P-9 antigen was used for assay standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The immunogen used for antibody production was prepared by Biosite Incorporated. PCR primers were made corresponding to sequence at the 5'-end of human MMP-9 and the coding. . .

of these clones (A4MP9peakl2) was verified at MacConnell Research (San Diego, CA) by the dideoxy chain termination method using a Sequatherm. sequencing kit (Epicenter Technologies, Madison, WI), oligonucleotide primers C, 5'-TTCTCAAGCCTCAGACAGTG - Y(SEQ ID NO:3), and D, 5'-CCTGGATGCAGGCTACTCTAG - Y(SEQ ID NO:4), that. . . suitable for transfection and the subsequent expression and purification of human MMP-9 was prepared from clone MMP9peakl2.2 using an EndoFree Plasmid Mega Kit as per manufacturer's recommendations (Qiagen, Valencia, CA). HEK 293 (Peak) cells were expanded into a T-75 flask from a lml frozen vial. . .

[01081 Assays for NUVIP-9 were performed using murine anti-XIMP-9 antibodies generated at Biosite Incorporated, using phage display and recombinant protein expression techniques. Cominercially available NIMP-9 antigen was used for assay

standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The concentration of MMP-9 was quantified by detecting the binding of alkaline
phosphatase-conjugated antibody. The minimal detectable concentration for the assay
was 0.3 ng/mL and the upper end of the reportable range was 2000 ng/mL.
. . .

[01091 Assays for Thrombus precursor Protein (TpPTM) were performed using
reagents obtained from American Biogenetic Sciences, Inc., Columbia,]M-Two
murine monoclonal antibodies that recognize different epitopes on the soluble fibrin
polymer were employed for the assay. The assay was calibrated using TpPTM supplied
by. . .

[01101 Assays for Monocyte Chemotactic protein-1 (MCP-1) were performed using
antibodies developed at Biosite. The assays were developed in an immunometric
(sandwich) format. The assays were calibrated with an in-house MCP- I.
. .
. . .
various forms of troponin I (TIC complex and total TnI) were performed using a commercially available goat anti-TnI for capture and antibodies
developed at Biosite as the enzyme-labeled conjugates. The assays were calibrated
with in-house TIC complex and TnI reference solutions. The minimal detectable
concentration. . .

[0112] Assays for fatty acid binding protein (FABP) were performed using commercially available monoclonal antibodies and a
commercially available FABP
antigen. The minimal detectable concentration was 6 ng/ml and the upper end of the
reportable range was. . .
. . .
in the
example above. Alternative or additional markers of myocardial injury include annexin
V, BNP and/or BNP-related peptides, P-enolase, creatine kinase-MB, glycogen
phosphorylase-BB, heart-type fatty
acid binding protein, phosphoglyceric acid
mutase-
MB, and S-100ao.

MMP-9 assay
[01241 Assays for MAV-9 were performed using murine anti-MMP-9 antibodies
generated at Biosite Incorporated, using phage display and recombinant protein
expression techniques. Commercially available NEVIP-9 antigen was used for assay
standardization (Calbiochem-Novabiochem Corporation,. . . on a robotic high-throughput platform
(TECAN Genesis RSP 200/8). The concentration of MMP-9 was quantified by detecting the binding of alkaline phosphatase-conjugated
antibody. All samples were
run in duplicate. The minimal detectable concentration for the assay was 3.0 ng/mL
and the upper end of the. . .

strategies can include, e.g., delivery of antisense compositions
in order to disrupt the synthesis of NWP-9; delivery of receptor-based
therapeutics
(e.g., an antibody composition directed to MMP-9 or a fragment
thereof); and/or
delivery of small molecule thrapeutics (e.g., heparin can decrease MMP-9
synthesis,
tetracycline antibiotics. . .

CLMEN. . . myocardial
injury is selected from the group consisting of annexin V, B-type
natriuretic peptide,
enolase, cardiac troponin I, creatine kinase-MB, glycogen
phosphorylase-BB, heart-
type fatty acid binding
protein, phosphoglyceric acid mutase-MB, and S- 1 00ao.

=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or
(daunomycin or daunorubicin)
188048 ANTI
185 ANTIS
188087 ANTI
(ANTI OR ANTIS)
79510 CANCER
30806 CANCERS
81924 CANCER
(CANCER OR CANCERS)
12783 ANTI (W) CANCER
35587 CHEMOTHE?
4414 ANTHRACYCL?
18658 DOX?
5135 ADRIAMYCIN
17 ADRIAMYCINS
5142 ADRIAMYCIN
(ADRIAMYCIN OR ADRIAMYCINS)
3555 DAUNOMYCIN
22 DAUNOMYCINS
3565 DAUNOMYCIN
(DAUNOMYCIN OR DAUNOMYCINS)
6682 DAUNORUBICIN
12 DAUNORUBICINS
6684 DAUNORUBICIN
(DAUNORUBICIN OR DAUNORUBICINS)
L18 49281 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR
ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> d his

(FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
L1 380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2 25686 S DOXORUBICIN OR ADRIAMYCIN
L3 2 S L2 AND L1
L4 748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5 32 S L4 AND L1
L6 8 S L5 NOT PY>2002
L7 2 S L6 AND ANTIBOD?

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
L8 57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9 41 S L8 AND ANTIBOD?
L10 6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

```
L11           2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
L12          12 S L9 NOT PY>2002
L13           9 S L12 AND KIT
L14           6 S L8/AB
L15          17 S L8/CLM
L16          19 S L15 OR L14
L17           3 S L16 AND L13
L18       49281 S (ANTI () CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR

=> s l18 and l17
L19           0 L18 AND L17

=> s l19 and 19
L20           0 L19 AND L9

=> s l18 and 19
L21           8 L18 AND L9

=> s l21 not py>2002
        481204 PY>2002
L22           3 L21 NOT PY>2002

=> d ibib 1-3

L22    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2001068851 PCTFULL  ED 20020822
TITLE (ENGLISH):         POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
TITLE (FRENCH):          NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES LES CODANT
INVENTOR(S):             PADIGARU, Muralidhara;
                         VERNET, Corine, A., M.;
                         FERNANDES, Elma;
                         SHIMKETS, Richard, A.;
                         SPADERNA, Steven, K.;
                         MAJUMDER, Kumud;
                         LI, Li
PATENT ASSIGNEE(S):      CURAGEN CORPORATION;
                         PADIGARU, Muralidhara;
                         VERNET, Corine, A., M.;
                         FERNANDES, Elma;
                         SHIMKETS, Richard, A.;
                         SPADERNA, Steven, K.;
                         MAJUMDER, Kumud;
                         LI, Li
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 2001068851         A2 20010920
DESIGNATED STATES
       W:                AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                         CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
                         IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
                         MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
                         TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
                         SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
                         CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
                         CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:       WO 2001-US7735        A  20010312
PRIORITY INFO.:          US 2000-60/188,316       20000310
                         US 2000-60/188,277       20000310
                         US 2000-60/189,139       20000314
                         US 2000-60/189,140       20000314
                         US 2000-60/190,401       20000317
                         US 2000-60/190,231       20000317
```

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000033083 PCTFULL ED 20020515
TITLE (ENGLISH): DIAGNOSIS OF STAGE OR AGGRESSIVENESS OF CANCER
TITLE (FRENCH): DIAGNOSTIC DE LA PHASE D'EVOLUTION OU DE L'AGRESSIVITE DE CANCERS
INVENTOR(S): JETT, Marti;
DAS, Rina;
NEILL, Roger
PATENT ASSIGNEE(S): WRAIR;
JETT, Marti;
DAS, Rina;
NEILL, Roger
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000033083	A1	20000608

DESIGNATED STATES
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1999-US28314 A 19991130
PRIORITY INFO.: US 1998-60/110,484 19981201

L22 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997035028 PCTFULL ED 20020514
TITLE (ENGLISH): CYTOSTATIN III
TITLE (FRENCH): CYTOSTATINE III
INVENTOR(S): NI, Jian;
YU, Guo-Liang;
GENTZ, Reiner, L.
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
NI, Jian;
YU, Guo-Liang;
GENTZ, Reiner, L.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735028	A1	19970925

DESIGNATED STATES
W: AM AU BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LT LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM UA US UZ VN AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1996-US3697 A 19960319

=> d kwic 2

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD BACKGROUND OF THE INVENTION
Although screening mammography and the increased use of breast conserving surgery
and adjuvant chemotherapy have improved the quality of life
and prolonged survival for women
with breast cancer, additional therapeutic strategies are needed to combat. . .

Modulation of mitogenesis by liver fatty acid binding protein, Cancer Metastasis Rev 13:317-
36, 1994.). In contrast, MDGI (H-FABP) appears only
in normal and not tumor mammary cells
(Grosse R, Boehmer FD, Langen P, Kurtz A, Lehmann W, Mieth M. . .
.
types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081:1-24, 1991). L-FABP exhibits different lipid binding characteristics from
that of A-FABP or H-FABP. L-FABP transfected into
rat hepatoma cells also mediates cell in-
duction by carcinogenic peroxisome proliferators (Khan SH and Sorof S.: Liver. . .

L-FABP is elevated significantly in metastatic or regenerating liver vs normal liver. This
is in stark contrast to H-FABP, also known as
mammary derived growth inhibitor (MDGI). It is
present only in normal lactating breast, and completely disappears in mammary. . . performed a similar study (to the eicosanoid generation in
hepatic cells) in MCF-7 cells transfected with a clone of the MDGI (H-FABP) gene or vector
alone. The inventors also have examined these pairs of cells to determine cell cycle pattern
changes related to MDGI. . .

identification of markers that define their degree of differentiation. Cancer Res 57:4111-7,
1997.). Although FABPs are intracellular proteins, H-
FABP has been detected in elevated levels
in plasma and urine of patients suffering from myocardial infarction, (Sohmiya K, Tanaka T,
Tsuji R,. . . III
had 37% reduction and grade IV had no A-FABP expression. A-FABP may act as a growth
inhibitor similar to the MDGI (H-FABP) protein in
breast cancer and loss of A-FABP expression
may serve as a prognostic marker for aggressive bladder cancer.

These results suggests that A-FAIBP and E-FA_BP may act as a tumor suppressors in
prostate cells similar to MDGI (H-FABP) in MCF-7
cells (Huynh H, Alpert L and Pollak M..
.
fluid but normal prostate cells did not secrete measurable amounts of this protein. In addition, previous studies have shown that a) H
-FABP was secreted into plasma
during severe myocardial infarction and b) E-FABP was decreased in urine in bladder cancer.

The inventors have shown that the pattern of B-, L-, I-FABPs, taken together, along with
decreases in A-, E-, and H-FABPs, are indicative of
the relative agressiveness of the cancer. The
pattern of FABI's provide potential markers to help patients choose a. . .

Furthermore, the normal cell-associated FABPs (E-, A-, and H-
FABPs) were decreased in tumor
cells (3 -II fold). In patient specimens of normal and tumor prostate tissue, these patterns were
repeated, in. . .
. . .

sample was used by doing a concentration curve for each sample. These biotin labeled PCR products were quantitated using streptavidin coated antibodies (Streptavidin
has very high affinity for Biotin) which was linked to HRP (Horse Radish Peroxidase) or a
fluorescent tag that was used. . .

. . .

(Bradford method, Bio Rad, CA) and then ELISA was
performed to evaluate the levels of the various FABI's by using specific antibodies to each of the
different types of FABPs. Antibodies such as heart FABP
antibody and Liver-FABP antibody
obtained from Research Diagnostics, Inc., Pleasant Hill Road, Flanders, NJ 07836 were used in
these tests. However, antibodies for the remaining FABPS can
also be developed and used. The
levels of these proteins were correlated to the stages of. . .

. . .

4) epidermis or psoriasis-associated (E-
FABP), 5) liver (L-FABP), 6) intestine (1-FABP), and 7) myelin or P2 (P2-FABP). As a group
A-FABP, H-FABP, B-FABP, and E-FABP in humans share
between 50-65% protein sequence
homology and contain a tyrosine near residue 20 that can be. . .

. . .

MCF-7 ADR cells. This allows the use of this drug when the patient starts showing drug resistance to the commonly used
chemotherapeutic drugs. This drug is
nontoxic to mice when tested for any change in body weight or by necropsy studies. This drug is
also not toxic to human bone marrow cells, which are effected the most during chemotherapy.

. . .

inhibitors of
eicosanoid metabolism on the growth of breast cancer cells. Inhibitors contemplated are those
currently used in clinical situations such as doxorubicin,
5FU, vinca alkaloids, adriamycin as
well as lipoxygenase inhibitors. The HPA drug can be given
simultaneously with or can be given
followed by exposing the cancerous. . . to block the growth of the cancerous cells and change the FABP profile to a normal cell FABP profile. Subsequent
27
applications of chemotherapeutic agents or inhibitor can be
given in a lower amount than
previous applications.

. . .

representing unique regions of each specific FABP. We will synthesize these peptides,
attach them to a carrier molecule and generate specific
antibodies for each of FABPs. These
30
antibodies are crucial for use in development of ELISA
procedures to detect each of the specific
FABI's in body fluids and, perhaps,. . .

CLMEN. . . 8 The method of claim 4, wherein said detecting comprises measuring the amount fatty
acid binding proteins in the sample with antibodies and
determining type of fatty acid
binding protein in the sample by ELISA.

. . .

9 The method of claim 5, wherein said detecting comprises measuring the amount fatty

acid binding proteins in the sample with antibodies and
determining type of fatty acid
binding protein in the sample by ELISA.

10 The method of claim 8, wherein said antibodies are specific
to at least one protein
selected from the group consisting of Liver-FABP, Intestinal-FABP,
Adipose-FABP,
CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

11 The method of claim 9, wherein said antibodies are specific
to at least one protein
selected from the group consisting of Liver-FABP, Intestinal-FABP,
Adipose-FABP,
CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

. . .
of-
a) detecting the amount of at least one fatty acid binding protein
present in a sample
of mammalian body fluid with antibodies specific to said fatty
acid binding
protein;
b) determining the difference in the amount of the at least one fatty
acid binding
protein. . .

. . .
the
steps of-
a) detecting the amount of at least one fatty acid binding protein
present in a sample
of mammalian tissue with antibodies specific to said fatty
acid binding protein;
39
b) detennining the difference in the amount of the at least one fatty
acid. . .

. . .
cell
FABP profile to a normal cell FABP profile; and
b) exposing the cancer cells to a first predetermined amount of a
chemotherapeutic
agent or cancer inhibitor sufficient to block the growth of the cells.

21 The method of claim 19, wherein said inhibitor is doxorubicin
, 5FU, vinca alkaloids or
lipoxygenase inhibitors.

26 The method of inhibiting growth of cancer cells of claim 19, further
comprising exposing the
cancer cells to a chemotherapeutic agent or inhibitor a second
time in a second lower amount
than said first predetermined amount.

. . .
of breast or. prostate cancer cells of claim 19, wherein the
method of inhibiting directed to breast cells and the known
chemotherapeutic agent or drug
is one of 5-flourouracil or adriamycin.

=> file dissab

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.07	92.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -0.75

FILE 'DISSABS' ENTERED AT 11:39:16 ON 19 DEC 2006

FILE COVERS 1861 TO 27 NOV 2006 (20061127/ED)

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)
```
         59809 H
            95 FABP
            29 FABPS
           102 FABP
                 (FABP OR FABPS)
            13 H-FABP
                 (H(W)FABP)
             1 HFABP
         59809 H
            95 FABP
            29 FABPS
           102 FABP
                 (FABP OR FABPS)
            13 H (W) FABP
         19262 HEART
          1651 HEARTS
         20021 HEART
                 (HEART OR HEARTS)
        138410 TYPE
         97741 TYPES
        211295 TYPE
                 (TYPE OR TYPES)
          7556 FATTY
             1 FATTIES
          7557 FATTY
                 (FATTY OR FATTIES)
         68494 ACID
         24901 ACIDS
         80503 ACID
                 (ACID OR ACIDS)
         49720 BINDING
           166 BINDINGS
         49793 BINDING
                 (BINDING OR BINDINGS)
         80601 PROTEIN
         44527 PROTEINS
         93270 PROTEIN
                 (PROTEIN OR PROTEINS)
             3 HEART-TYPE FATTY ACID BINDING PROTEIN
                 (HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)
         19262 HEART
          1651 HEARTS
         20021 HEART
                 (HEART OR HEARTS)
        138410 TYPE
         97741 TYPES
        211295 TYPE
```

```
                (TYPE OR TYPES)
             0 FACTTY
         68494 ACID
         24901 ACIDS
         80503 ACID
                (ACID OR ACIDS)
             0 HEART TYPE FACTTY ACID
                (HEART(W)TYPE(W)FACTTY(W)ACID)
         49720 BINDING
           166 BINDINGS
         49793 BINDING
                (BINDING OR BINDINGS)
         80601 PROTEIN
         44527 PROTEINS
         93270 PROTEIN
                (PROTEIN OR PROTEINS)
          7721 BINDING PROTEIN
                (BINDING(W)PROTEIN)
             0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L23         15 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
               BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s l23 and antibod?
         19910 ANTIBOD?
L24          3 L23 AND ANTIBOD?

=> d ibib 1-3

L24  ANSWER 1 OF 3  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   2001:30986  DISSABS   Order Number: AAI9991903
TITLE:              Mechanisms of fatty acid transport and uptake by adipocyte
                    fatty acid-binding protein
AUTHOR:             Liou, Heng-Ling [Ph.D.]; Storch, Judith [adviser]
CORPORATE SOURCE:   Rutgers The State University of New Jersey - New Brunswick
                    (0190)
SOURCE:             Dissertation Abstracts International, (2000) Vol. 61, No.
                    10B, p. 5242. Order No.: AAI9991903. 251 pages.
                    ISBN: 0-599-99576-9.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English

L24  ANSWER 2 OF 3  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   97:77250  DISSABS   Order Number: AAR9800797
TITLE:              STRUCTURE, FUNCTION AND DISTRIBUTION OF LIPID BINDING
                    PROTEINS IN MOUSE BRAIN (HEART FATTY ACID BINDING PROTEIN,
                    AGING)
AUTHOR:             PU, LIXIA [PH.D.]; SCHROEDER, FRIEDHELM [advisor]
CORPORATE SOURCE:   TEXAS A&M UNIVERSITY (0803)
SOURCE:             Dissertation Abstracts International, (1997) Vol. 58, No.
                    7B, p. 3597. Order No.: AAR9800797. 147 pages.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English
ENTRY DATE:         Entered STN: 19971124
                    Last Updated on STN: 19971124

L24  ANSWER 3 OF 3  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   94:22128  DISSABS   Order Number: AARC349190 (not available
                    for sale by UMI)
TITLE:              HETEROLOGOUS EXPRESSION OF THE BOVINE CARDIAC FATTY
                    ACID-BINDING PROTEIN (H-FABP) IN THE
```

YEAST YARROWIA LIPOLYTICA: BIOCHEMICAL AND PHYSIOLOGICAL STUDIES
HETEROLOGE EXPRESSION DES FETTSAEURE-BINDENDEN PROTEINS AUS RINDERHERZ (H-FABP) IN DER HEFE
YARROWIA LIPOLYTICA: BIOCHEMISCHE UND PHYSIOLOGISCHE UNTERSUCHUNGEN

AUTHOR: BAUER, RONALD EDUARD [DR.TECHN.]
CORPORATE SOURCE: TECHNISCHE UNIVERSITAET GRAZ (AUSTRIA) (5800)
SOURCE: Dissertation Abstracts International, (1993) Vol. 55, No. 2C, p. 449. Order No.: AARC349190 (not available for sale by UMI). UNIVERSITY LIBRARY, TECHNISCHE UNIVERSITAT GRAZ, TECHNIKERSTRASSE 4, A-8010 GRAZ, AUSTRIA.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: German
ENTRY DATE: Entered STN: 19940607
Last Updated on STN: 19940607

```
=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or
(daunomycin or daunorubicin)
         27176 ANTI
            10 ANTIS
         27182 ANTI
                 (ANTI OR ANTIS)
         15632 CANCER
          2379 CANCERS
         16412 CANCER
                 (CANCER OR CANCERS)
           488 ANTI (W) CANCER
          2780 CHEMOTHE?
           247 ANTHRACYCL?
           825 DOX?
           257 ADRIAMYCIN
            92 DAUNOMYCIN
             1 DAUNOMYCINS
            92 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
            78 DAUNORUBICIN
L25       4221 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR
               ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> s l24 and l25
L26          0 L24 AND L25

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.57	96.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.75

STN INTERNATIONAL LOGOFF AT 11:40:15 ON 19 DEC 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 22	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 23	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 24	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 25	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 27	DEC 18	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 28	DEC 18	CA/CAplus patent kind codes updated
NEWS 29	DEC 18	MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 30	DEC 18	MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 18 Dec 2006 (20061218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)
H-FABP IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)
2712469 H
2568 FABP
259 FABPS
2580 FABP
(FABP OR FABPS)
319 H-FABP
(H(W)FABP)
93 HFABP
1 HFABPS
93 HFABP
(HFABP OR HFABPS)
2712469 H
2568 FABP

```
          259 FABPS
         2580 FABP
                (FABP OR FABPS)
          319 H (W) FABP
       335556 HEART
        28346 HEARTS
       337380 HEART
                (HEART OR HEARTS)
      1745637 TYPE
       598781 TYPES
      2208661 TYPE
                (TYPE OR TYPES)
       373756 FATTY
           14 FATTIES
       373760 FATTY
                (FATTY OR FATTIES)
      4259872 ACID
      1553426 ACIDS
      4757683 ACID
                (ACID OR ACIDS)
       953897 BINDING
         2080 BINDINGS
       954489 BINDING
                (BINDING OR BINDINGS)
      1948078 PROTEIN
      1364406 PROTEINS
      2269874 PROTEIN
                (PROTEIN OR PROTEINS)
          128 HEART-TYPE FATTY ACID BINDING PROTEIN
                (HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)
       335556 HEART
        28346 HEARTS
       337380 HEART
                (HEART OR HEARTS)
      1745637 TYPE
       598781 TYPES
      2208661 TYPE
                (TYPE OR TYPES)
            1 FACTTY
      4259872 ACID
      1553426 ACIDS
      4757683 ACID
                (ACID OR ACIDS)
            0 HEART TYPE FACTTY ACID
                (HEART(W)TYPE(W)FACTTY(W)ACID)
       953897 BINDING
         2080 BINDINGS
       954489 BINDING
                (BINDING OR BINDINGS)
      1948078 PROTEIN
      1364406 PROTEINS
      2269874 PROTEIN
                (PROTEIN OR PROTEINS)
       154312 BINDING PROTEIN
                (BINDING(W)PROTEIN)
            0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L1          380 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
                BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s doxorubicin or adriamycin
          15810 DOXORUBICIN
             28 DOXORUBICINS
          15812 DOXORUBICIN
                (DOXORUBICIN OR DOXORUBICINS)
          10770 ADRIAMYCIN
```

```
           16 ADRIAMYCINS
        10772 ADRIAMYCIN
                (ADRIAMYCIN OR ADRIAMYCINS)
L2      25686 DOXORUBICIN OR ADRIAMYCIN

=> a l2 and l1
A IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and l1
L3           2 L2 AND L1

=> d ibib

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2004:450309  CAPLUS
DOCUMENT NUMBER:         141:36901
TITLE:                   Limited role of N-terminal phosphoserine residues in
                         the activation of transcription by p53
AUTHOR(S):               Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna
                         L.; Agarwal, Archana; Stanhope-Baker, Patricia;
                         Williams, Bryan R. G.; Stark, George R.
CORPORATE SOURCE:        Department of Molecular Biology, Lerner Research
                         Institute, Cleveland Clinic Foundation, Cleveland, OH,
                         44195, USA
SOURCE:                  Oncogene (2004), 23(25), 4477-4487
                         CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER:               Nature Publishing Group
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         87    THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d ibib 1-2

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2004:450309  CAPLUS
DOCUMENT NUMBER:         141:36901
TITLE:                   Limited role of N-terminal phosphoserine residues in
                         the activation of transcription by p53
AUTHOR(S):               Jackson, Mark W.; Agarwal, Mukesh K.; Agarwal, Munna
                         L.; Agarwal, Archana; Stanhope-Baker, Patricia;
                         Williams, Bryan R. G.; Stark, George R.
CORPORATE SOURCE:        Department of Molecular Biology, Lerner Research
                         Institute, Cleveland Clinic Foundation, Cleveland, OH,
                         44195, USA
SOURCE:                  Oncogene (2004), 23(25), 4477-4487
                         CODEN: ONCNES; ISSN: 0950-9232
PUBLISHER:               Nature Publishing Group
DOCUMENT TYPE:           Journal
LANGUAGE:                English
REFERENCE COUNT:         87    THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:        2003:797013  CAPLUS
DOCUMENT NUMBER:         139:286301
TITLE:                   Method of judging cardiotoxicity of anthracycline-type
                         anticancer chemical therapeutic by detecting human
                         H-FABP and reagent therefor
INVENTOR(S):             Kitayama, Hitoshi; Ohkaru, Yasuhiko
PATENT ASSIGNEE(S):      Dainippon Pharmaceutical Co., Ltd., Japan
```

SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003083486	A1	20031009	WO 2003-JP3924	20030328
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003220882	A1	20031013	AU 2003-220882	20030328
EP 1491896	A1	20041229	EP 2003-715565	20030328
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2005202513	A1	20050915	US 2004-509571	20040929
PRIORITY APPLN. INFO.:			JP 2002-93688 A	20020329
			WO 2003-JP3924 W	20030328

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s cancer? or tumor? or neoplas?
        315544 CANCER?
        452001 TUMOR?
        474391 NEOPLAS?
L4      748872 CANCER? OR TUMOR? OR NEOPLAS?

=> s l4 and l1
L5          32 L4 AND L1

=> s l5 not py>2002
       4707679 PY>2002
L6          8 L5 NOT PY>2002

=> s l6 and antibod?
        479076 ANTIBOD?
L7          2 L6 AND ANTIBOD?

=> d ibib 1-2

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:       2000:376177  CAPLUS
DOCUMENT NUMBER:        133:248010
TITLE:                  Identification of differentially expressed genes in
                        cardiac hypertrophy by analysis of expressed sequence
                        tags
AUTHOR(S):              Hwang, David M.; Dempsey, Adam A.; Lee, Cheuk-Yu;
                        Liew, Choong-Chin
CORPORATE SOURCE:       Cardiac Gene Unit, Department of Laboratory Medicine
                        and Pathobiology, Centre for Cardiovascular Research,
                        Toronto Hospital, University of Toronto, Toronto, ON,
                        M5G 1L5, Can.
SOURCE:                 Genomics (2000), 66(1), 1-14
                        CODEN: GNMCEP; ISSN: 0888-7543
PUBLISHER:              Academic Press
```

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 84 THERE ARE 84 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:682528 CAPLUS
DOCUMENT NUMBER: 129:299045
TITLE: Cloning and cDNA sequence of human fatty acid-binding protein
INVENTOR(S): Hillman, Jennifer L.; Shah, Purvi
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845440	A1	19981015	WO 1998-US7084	19980408
W: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868942	A	19981030	AU 1998-68942	19980408
PRIORITY APPLN. INFO.:			US 1997-825783 A2	19970408
			WO 1998-US7084 W	19980408

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 2

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . polynucleotides which identify and encode Hu-FABP. Nucleic acids encoding Hu-FABP were first identified in Incyte clone 2581906 from a kidney tumor tissue cDNA library through a computer-generated search for amino acid sequence alignments; a consensus sequence was derived from overlapping and/or. . . . acids in length and chemical and structural homol. with FABP from chick retina, B-FABP from rat and mouse brain, and H-FABP from mouse and human heart.
Northern anal. shows the most abundant expression of Hu-FABP in fetal brain, which suggests a developmental role for this mol. In adults, Hu-FABP is found primarily in cancer-associated tissues, particularly, brain, kidney, and breast. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of Hu-FABP, as. . .
IT Antibodies
Probes (nucleic acid)
RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(cloning and cDNA sequence of human fatty acid-binding protein)

=> file pctfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	59.03	59.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -0.75 -0.75

FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 19 DEC 2006 <20061219/UP>
MOST RECENT UPDATE WEEK: 200650 <200650/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE
http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)
485934 H
291 FABP
51 FABPS
307 FABP
(FABP OR FABPS)
45 H-FABP
(H(W)FABP)
8 HFABP
485934 H
291 FABP
51 FABPS
307 FABP
(FABP OR FABPS)
45 H (W) FABP
64305 HEART
4368 HEARTS
65049 HEART
(HEART OR HEARTS)
651740 TYPE
384590 TYPES
710359 TYPE
(TYPE OR TYPES)
75579 FATTY
2 FATTIES
75580 FATTY
(FATTY OR FATTIES)
286591 ACID
191691 ACIDS
297259 ACID
(ACID OR ACIDS)
138670 BINDING
2428 BINDINGS
139156 BINDING
(BINDING OR BINDINGS)
144350 PROTEIN
122052 PROTEINS
159658 PROTEIN
(PROTEIN OR PROTEINS)
18 HEART-TYPE FATTY ACID BINDING PROTEIN
(HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)
64305 HEART
4368 HEARTS
65049 HEART
(HEART OR HEARTS)
651740 TYPE

```
        384590 TYPES
        710359 TYPE
                 (TYPE OR TYPES)
             0 FACTTY
        286591 ACID
        191691 ACIDS
        297259 ACID
                 (ACID OR ACIDS)
             0 HEART TYPE FACTTY ACID
                 (HEART(W)TYPE(W)FACTTY(W)ACID)
        138670 BINDING
          2428 BINDINGS
        139156 BINDING
                 (BINDING OR BINDINGS)
        144350 PROTEIN
        122052 PROTEINS
        159658 PROTEIN
                 (PROTEIN OR PROTEINS)
         31430 BINDING PROTEIN
                 (BINDING(W)PROTEIN)
             0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L8          57 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
               BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s l8 and antibod?
         93871 ANTIBOD?
L9          41 L8 AND ANTIBOD?

=> s l9 and doxorucicin or daunomycin or anthracyclin?
             1 DOXORUCICIN
          3555 DAUNOMYCIN
            22 DAUNOMYCINS
          3565 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
          4401 ANTHRACYCLIN?
L10       6166 L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?

=> s l9 and (doxorucicin or daunomycin or anthracyclin?)
             1 DOXORUCICIN
          3555 DAUNOMYCIN
            22 DAUNOMYCINS
          3565 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
          4401 ANTHRACYCLIN?
L11         2 L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> d ibib 1-2

L11    ANSWER 1 OF 2     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2006131928 PCTFULL  ED 20061219  EW 200650
TITLE (ENGLISH):         NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS
                         AND METHODS OF USE THEREOF FOR DIAGNOSIS
TITLE (FRENCH):          NOUVELLES SEQUENCES DE NUCLEOTIDES ET D'ACIDES AMINES,
                         LEURS DOSAGES ET METHODES D'UTILISATION EN VUE DU
                         DIAGNOSTIC
INVENTOR(S):             SAMEAH-GREENWALD, Shirley, 33/7 Arlozorov Street, 44453
                         Kfar-saba, IL;
                         NOVIK, Amit, 31 Hasayfan Street, 40600 Tel-mond, IL;
                         WALLACH, Shira, 40 Bnei Brit Street, 45265
                         Hod-hasharon, IL;
                         POLLOCK, Sarah, 16/2 Hoshea Street, 63506 Tel-aviv, IL;
                         BAZAK, Lily, 46 Raynes Street, 53461 Givatayim, IL;
                         TSYPKIN, Elena, 105/7 Even Gvirol Street, 64046
                         Tel-aviv, IL;
                         COJOCARU, Gad, S., 41/7 Hasayfan Street, 47248
```

Ramat-hasharon, IL;
SELLA-TAVOR, Osnat, 18 Kfar Kish, 19330 Kfar Kish, IL

PATENT ASSIGNEE(S): COMPUGEN LTD., 72 Pinchas Rosen Street, 69512 Tel Aviv, IL

AGENT: WEBB, Cynthia et al.$, Webb & Associates, P.O. Box 2189, 76121 Rehovot$, IL

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2006131928	A2	20061214

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2006-IL676	A 20060608
PRIORITY INFO.:	US 2005-60688320	20050608
	US 2005-60699427	20050715
	US 2005-60704414	20050802

L11 ANSWER 2 OF 2 PCTFULL COPYRIGHT 2006 Univentio on STN

ACCESSION NUMBER: 2006026785 PCTFULL ED 20060403 EW 200610

TITLE (ENGLISH): COMPOSITIONS AND METHODS FOR MODULATING PGC-1a TO TREAT NEUROLOGICAL DISEASES AND DISORDERS

TITLE (FRENCH): COMPOSITIONS ET PROCEDES DE MODULATION DE PGC-1$G(A) POUR LE TRAITEMENT DE MALADIES ET DE TROUBLES NEUROLOGIQUES

INVENTOR(S): LIN, Jiandie, 79 Chestnut Street, Apt.#1, Brookline, MA 02445, US;
SPIEGELMAN, Bruce, M., 271 Waban Avenue, Waban, MA 02168, US

PATENT ASSIGNEE(S): DANA-FARBER CANCER INSTITUTE, INC., 44 Binney Street, Boston, MA 02115-6084, US

AGENT: SMITH, DeAnn, F. et al.$, Patent Group, Foley Hoag LLP, Seaport World Trade Center West, 155 Seaport Blvd., Boston, MA 02210; 02210$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2006026785	A2	20060309

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

RW (ARIPO): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

```
APPLICATION INFO.:      WO 2005-US31715      A  20050906
PRIORITY INFO.:         US 2004-60607412        20040903


=> d his

     (FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

     FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
L1           380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2         25686 S DOXORUBICIN OR ADRIAMYCIN
L3             2 S L2 AND L1
L4        748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5            32 S L4 AND L1
L6             8 S L5 NOT PY>2002
L7             2 S L6 AND ANTIBOD?

     FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
L8            57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9            41 S L8 AND ANTIBOD?
L10         6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11            2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)

=> s l9 not py>2002
        481204 PY>2002
L12         12 L9 NOT PY>2002

=> s l12 and kit
         81427 KIT
         38881 KITS
         87623 KIT
                 (KIT OR KITS)
L13          9 L12 AND KIT

=> s l8/ab
         16209 H/AB
            16 FABP/AB
             1 FABPS/AB
            17 FABP/AB
                 ((FABP OR FABPS)/AB)
             6 H-FABP/AB
                 ((H(W)FABP)/AB)
             0 HFABP/AB
         16209 H/AB
            16 FABP/AB
             1 FABPS/AB
            17 FABP/AB
                 ((FABP OR FABPS)/AB)
             6 H/AB (W) FABP/AB
          5057 HEART/AB
            33 HEARTS/AB
          5073 HEART/AB
                 ((HEART OR HEARTS)/AB)
         87567 TYPE/AB
         15286 TYPES/AB
         98263 TYPE/AB
                 ((TYPE OR TYPES)/AB)
          6744 FATTY/AB
         63647 ACID/AB
         17172 ACIDS/AB
         73135 ACID/AB
                 ((ACID OR ACIDS)/AB)
         16377 BINDING/AB
           141 BINDINGS/AB
         16461 BINDING/AB
```

```
                ((BINDING OR BINDINGS)/AB)
         25316 PROTEIN/AB
         14190 PROTEINS/AB
         34108 PROTEIN/AB
                ((PROTEIN OR PROTEINS)/AB)
             0 HEART-TYPE FATTY ACID BINDING PROTEIN/AB
                ((HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)/AB)
          5057 HEART/AB
            33 HEARTS/AB
          5073 HEART/AB
                ((HEART OR HEARTS)/AB)
         87567 TYPE/AB
         15286 TYPES/AB
         98263 TYPE/AB
                ((TYPE OR TYPES)/AB)
             0 FACTTY/AB
         63647 ACID/AB
         17172 ACIDS/AB
         73135 ACID/AB
                ((ACID OR ACIDS)/AB)
             0 HEART TYPE FACTTY ACID/AB
                ((HEART(W)TYPE(W)FACTTY(W)ACID)/AB)
         16377 BINDING/AB
           141 BINDINGS/AB
         16461 BINDING/AB
                ((BINDING OR BINDINGS)/AB)
         25316 PROTEIN/AB
         14190 PROTEINS/AB
         34108 PROTEIN/AB
                ((PROTEIN OR PROTEINS)/AB)
          1255 BINDING PROTEIN/AB
                ((BINDING(W)PROTEIN)/AB)
             0 HEART TYPE FACTTY ACID/AB (W) BINDING PROTEIN/AB
L14          6 (H-FABP/AB OR (HFABP/AB) OR (H/AB (W) FABP/AB) OR (HEART-TYPE
               FATTY ACID BINDING PROTEIN/AB) OR (HEART TYPE FACTTY ACID/AB
              (W) BINDING PROTEIN/AB))

=> s l8/clm
        190960 H/CLM
            60 FABP/CLM
            14 H-FABP/CLM
                ((H(W)FABP)/CLM)
             1 HFABP/CLM
        190960 H/CLM
            60 FABP/CLM
            14 H/CLM (W) FABP/CLM
         11386 HEART/CLM
        104803 TYPE/CLM
         14215 FATTY/CLM
        136223 ACID/CLM
         40435 BINDING/CLM
         52853 PROTEIN/CLM
             6 HEART-TYPE FATTY ACID BINDING PROTEIN/CLM
                ((HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)/CLM)
         11386 HEART/CLM
        104803 TYPE/CLM
             0 FACTTY/CLM
        136223 ACID/CLM
             0 HEART TYPE FACTTY ACID/CLM
                ((HEART(W)TYPE(W)FACTTY(W)ACID)/CLM)
         40435 BINDING/CLM
         52853 PROTEIN/CLM
          3331 BINDING PROTEIN/CLM
                ((BINDING(W)PROTEIN)/CLM)
             0 HEART TYPE FACTTY ACID/CLM (W) BINDING PROTEIN/CLM
```

```
L15          17 (H-FABP/CLM OR (HFABP/CLM) OR (H/CLM (W) FABP/CLM) OR (HEART-TYP
                E FATTY ACID BINDING PROTEIN/CLM) OR (HEART TYPE FACTTY ACID/CLM
                (W) BINDING PROTEIN/CLM))

=> s l15 or l14
L16          19 L15 OR L14

=> d his

     (FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

     FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
L1          380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2        25686 S DOXORUBICIN OR ADRIAMYCIN
L3            2 S L2 AND L1
L4       748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5           32 S L4 AND L1
L6            8 S L5 NOT PY>2002
L7            2 S L6 AND ANTIBOD?

     FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
L8           57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9           41 S L8 AND ANTIBOD?
L10        6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
L11           2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
L12          12 S L9 NOT PY>2002
L13           9 S L12 AND KIT
L14           6 S L8/AB
L15          17 S L8/CLM
L16          19 S L15 OR L14

=> s l16 and l13
L17           3 L16 AND L13

=> d ibib 1-3

L17    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2002089657 PCTFULL  ED 20021121  EW 200246
TITLE (ENGLISH):         DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND
                         METHODS OF USE THEREOF
TITLE (FRENCH):          MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS
                         ET LEURS METHODES D'UTILISATION
INVENTOR(S):             VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
                         92025, US [US, US];
                         DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego,
                         CA 92126, US [US, US];
                         KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
                         92121, US [US, US];
                         BUECHLER, Kenneth, F., 12523 Manifesto Place, San
                         Diego, CA 92130, US [US, US]
PATENT ASSIGNEE(S):      BIOSITE, INC., 11030 Roselle Street, San Diego, CA
                         92121, US [US, US], for all designates States except
                         US;
                         VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA
                         92025, US [US, US], for US only;
                         DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego,
                         CA 92126, US [US, US], for US only;
                         KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA
                         92121, US [US, US], for US only;
                         BUECHLER, Kenneth, F., 12523 Manifesto Place, San
                         Diego, CA 92130, US [US, US], for US only
AGENT:                   WARBURG, Richard, J.$, Foley & Lardner, P.O. Box 80278,
                         San Diego, CA 92138-0278$, US
LANGUAGE OF FILING:      English
LANGUAGE OF PUBL.:       English
```

DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002089657	A2	20021114

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2002-US14219 A 20020504
PRIORITY INFO.: US 2001-60/288,871 20010504
US 2001-60/315,642 20010828

L17 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2001067108 PCTFULL
no bibliographic data available - please use FPI for PI information
DESIGNATED STATES

L17 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997035878 PCTFULL ED 20020514
TITLE (ENGLISH): THE PORCINE HEART FATTY ACID-BINDING PROTEIN ENCODING GENE AND METHODS TO IDENTIFY POLYMORPHISMS ASSOCIATED WITH BODY WEIGHT
TITLE (FRENCH): GENE CODANT UNE PROTEINE SE LIANT A UN ACIDE GRAS DU COEUR DE PORC ET PROCEDE D'IDENTIFICATION DES CARACTERISTIQUES DU POLYMORPHISME RESPONSABLES DU POIDS DU CORPS
INVENTOR(S): GERBENS, Frans
PATENT ASSIGNEE(S): DALLAND B.V.;
PROVA B.V.;
STAMBOEK ZUID B.V.;
NOORD NEDERLANDS VARKENSSTAMBOEK B.V.;
INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID (ID-DLO);
GERBENS, Frans
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735878	A2	19971002

DESIGNATED STATES
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU GH KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
APPLICATION INFO.: WO 1997-NL157 A 19970327
PRIORITY INFO.: NL 1996-96200855.3 19960328

=> d ibib kwic 1

L17 ANSWER 1 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2002089657 PCTFULL ED 20021121 EW 200246
TITLE (ENGLISH): DIAGNOSTIC MARKERS OF ACUTE CORONARY SYNDROMES AND METHODS OF USE THEREOF

TITLE (FRENCH): MARQUEURS DIAGNOSTIQUES DE SYNDROMES CORONAIRES AIGUS ET LEURS METHODES D'UTILISATION

INVENTOR(S): VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA 92025, US [US, US];
DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego, CA 92126, US [US, US];
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA 92121, US [US, US];
BUECHLER, Kenneth, F., 12523 Manifesto Place, San Diego, CA 92130, US [US, US]

PATENT ASSIGNEE(S): BIOSITE, INC., 11030 Roselle Street, San Diego, CA 92121, US [US, US], for all designates States except US;
VALKIRS, Gunars, E., 2893 Paseo del Sol, Escondido, CA 92025, US [US, US], for US only;
DAHLEN, Jeffrey, R., 10555 Kemmerton Road, San Diego, CA 92126, US [US, US], for US only;
KIRCHICK, Howard, 5449 Panoramic Lane, San Diego, CA 92121, US [US, US], for US only;
BUECHLER, Kenneth, F., 12523 Manifesto Place, San Diego, CA 92130, US [US, US], for US only

AGENT: WARBURG, Richard, J.$, Foley & Lardner, P.O. Box 80278, San Diego, CA 92138-0278$, US

LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2002089657	A2	20021114

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2002-US14219	A	20020504
PRIORITY INFO.:	US 2001-60/288,871		20010504
	US 2001-60/315,642		20010828

DETD . . . annexin V, B-type natriuretic peptide, P-enolase, cardiac troponin I (free and/or complexed), cardiac troponin T (free and/or coinplexed), creatine kinase-MB, glycogen phosphorylase-BB, heart-type fatty acid binding protein, phosphoglyceric acid mutase-MB, and S-100ao. These specific markers are described in detail hereinafter.

[00381 In a further aspect, the invention relates to kits for determining the diagnosis or prognosis of a patient. These kits preferably comprise devices and reagents for measuring one or more marker levels in a patient sample, and instructions for performing the assay. Optionally, the kits may contain one or more means for converting marker level(s) to a prognosis. Such kits preferably contain sufficient

reagents to perform one or more such determinations.

al., Ain. J. Einerg. Med 17:225-229, 1999). This apparent non-specificity may be related to the quality and specificity of the antibodies used in the immunoassay. cTnI is released into the bloodstream following cardiac cell death. The plasma concentration of cTnI in patients with. . .

[00591 Heart-type fatty acid binding protein (H-FABP) is a cytosolic 15 kDa lipid-binding protein involved in lipid metabolism. Heart-type FABP antigen is found not only in heart tissue,. . . and Maatman, R.G., Prog. Lipid Res. 34:17-52,1995). The normal plasma concentration of FABP is < 6 ng/ml (400 pM). The plasma H-FABP concentration is elevated in patients with AMI and unstable angina (Ishii, J. et al., Clin. Chem. 43:1372-1378, 1997; Tsuji, R. et al., Int. J Cardiol. 41:209-217, 1993). Furthermore, H-FABP may be usefal in estimating infarct size in patients with AMI (Glatz, U. et al., Br.

Heart J. 71:13 5 -140, 1994). Myocardial tissue as a source of H -FABP can be confirmed by determining the ratio of myoglobin/FABP (grams/grams). A ratio of approximately 5 indicates that FABP is of myocardial origin,. . . while a higher ratio indicates skeletal muscle sources (Van Nieuwenhoven, F.A. et al., Circulation 92:2848-2854, 1995). Because of the presence of H-FABP in skeletal muscle, kidney and brain, elevations in the plasma H-FABP concentration may be associated with skeletal muscle injury, renal disease, or stroke. H-FABP is released into the bloodstream following cardiac tissue necrosis. The plasma H-FABP concentration can be significantly elevated 1-2 hours after the onset of chest pain, earlier than CK-MB and myoglobin (Tsuji, R. et al.,. . .

Additionally, H-FABP is rapidly cleared from the bloodstream, and plasma concentrations return to baseline after 24 hours after AMI onset (Glatz, J.F. et. . .

mediate crosslinking of platelets to vascular subendothelium, respectively. Measurement of any of these vWF forms, when used in an assay that employs antibodies specific for'the protease cleavage domain may allow assays to be used to determine the circulating concentration of various vWF forms in. . .

TpPTMmay also be useful in determining the severity of unstable angina. American Biogenetic Sciences, hic. instructs users of the TpPTm ELISA assay kit to collect blood using citrate as an anticoagulant, and they recommend against using EDTA. The effect of the anticoagulant used during. . .

in the art (for example, the measurement of marker RNA levels). The presence or amount of a marker is generally detennined using antibodies specific for each marker and detecting specific binding. Any suitable immunoassay may be utilized, for example, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. Specific immunological binding of the antibody to the marker can be detected directly or indirectly. Direct labels include fluorescent or luminescent tags, metals, dyes, radionuclides, and the like, attached to the antibody. Indirect labels include various enzymes well known in the art, such as alkaline phosphatase, horseradish peroxidase and the like.

[00981 The use of immobilized antibodies specific for the markers is also contemplated by the present invention. The antibodies could be immobilized onto a variety of solid supports, such as magnetic or chromatographic matrix particles, the surface of an assay place. . .. of a solid substrate material (such as plastic, nylon, paper), and the like. An assay strip could be prepared by coating the antibody or a plurality of antibodies in an array on solid support. This strip
55
could then be dipped into the test sample and then processed quickly through. . .

[01021 In another embodiment, the present invention provides a kit for the analysis of markers. Such a kit preferably comprises devises and reagents for the analysis of at least one test sample and instructions for perfonning the assay. Optionally the kits may contain one or more means for converting a marker level to a diagnosis or prognosis of
I 0 the patient.

[01041 Markers were measured using standard immunoassay techniques. These techniques involved the use of antibodies to specifically bind the protein targets. A monoclonal antibody directed against a selected marker was biotinylated using N-hydroxysuccinimide biotin (NHS-biotin) at a ratio of about 5 NHS-biotin moieties per antibody. The antibody-biotin conjugate was then added to wells of a standard avidin 384 well microtiter plate, and antibody conjugate not bound to the plate was removed. This formed the anti-marker in the microtiter plate. Another monoclonal
57
antibody directed against the same marker was conjugated to alkaline phosphatase using succinimidyl 4-[N-maleimidomethyl]-cyclohexane- 1 -carboxylate (SMCC) and N-succinimidyl 3-[2-pyridyldithio]propionate (SPDP) (Pierce,. . .

[01051 Imrnunoassays were performed on a TECAN Genesis RSP 200/8 Workstation. Biotinylated antibodies were pipetted into microtiter plate wells previously coated with avidin and incubated for 60 min. The solution containing unbound antibody was removed, and the cells were washed with a wash buffer, consisting of 20 mM borate (pH 7.42) containing 15 0. . . wells, and incubated for 60 min. The sample was then removed and the wells were washed with a wash buffer. The antibody- alkaline phosphatase conjugate was then added to the wells and incubated for an additional 60 min, after which time, the antibody conjugate was removed and the wells were washed with a wash buffer. A substrate, (AttoPhos], Promega, Madison, WI) was added to. . .

[01061 Assays for BNP were performed using murine anti-BNP monoclonal antibody 106.3 obtained from Scios Incorporated (Sunnyvale, CA). The hybridoma cell line secreting mAb 106.3 was generated from a fusion between FOX-NY cells and spleen cells from a Balb/c mouse immunized with human BNP 1-32 conjugated to BSA. A second murine anti-BNP antibody was produced by Biosite Incorporated (San Diego, CA) by antibody phage display as described previously (US Patent No.

[01071 Assays for MMP-9 were performed using murine anti-MMP-9 antibodies generated by Biosite Incorporated using phage display and recombinant protein expression as described previously (`US Patent No '. 6,057,098). Commercially available M1\4P-9 antigen was used for assay standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The immunogen used for antibody production was prepared by Biosite Incorporated. PCR primers were made corresponding to sequence at the 5'-end of human MMP-9 and the coding. . .

. . .

of these clones (A4MP9peakl2) was verified at MacConnell Research (San Diego, CA) by the dideoxy chain termination method using a Sequatherm. sequencing kit (Epicenter Technologies, Madison, WI), oligonucleotide primers C, 5'-TTCTCAAGCCTCAGACAGTG - Y(SEQ ID NO:3), and D, 5'-CCTGGATGCAGGCTACTCTAG - Y(SEQ ID NO:4), that. . . suitable for transfection and the subsequent expression and purification of human MMP-9 was prepared from clone MMP9peakl2.2 using an EndoFree Plasmid Mega Kit as per manufacturer's recommendations (Qiagen, Valencia, CA). HEK 293 (Peak) cells were expanded into a T-75 flask from a lml frozen vial. . .

[01081 Assays for NUVIP-9 were performed using murine anti-XIMP-9 antibodies generated at Biosite Incorporated, using phage display and recombinant protein expression techniques. Cominercially available NIMP-9 antigen was used for assay

standardization (Calbiochem-Novabiochem Corporation, San Diego, CA). The concentration of MMP-9 was quantified by detecting the binding of alkaline
phosphatase-conjugated antibody. The minimal detectable concentration for the assay
was 0.3 ng/mL and the upper end of the reportable range was 2000 ng/mL.

[01091 Assays for Thrombus precursor Protein (TpPTM) were performed using
reagents obtained from American Biogenetic Sciences, Inc., Columbia,]M-Two
murine monoclonal antibodies that recognize different epitopes on the soluble fibrin
polymer were employed for the assay. The assay was calibrated using TpPTM supplied
by. . .

[01101 Assays for Monocyte Chemotactic protein-1 (MCP-1) were performed using
antibodies developed at Biosite. The assays were developed in an immunometric
(sandwich) format. The assays were calibrated with an in-house MCP- I.

various forms of troponin I (TIC complex and total TnI) were performed using a commercially available goat anti-TnI for capture and antibodies
developed at Biosite as the enzyme-labeled conjugates. The assays were calibrated
with in-house TIC complex and TnI reference solutions. The minimal detectable
concentration. . .

[0112] Assays for fatty acid binding protein (FABP) were performed using commercially available monoclonal antibodies and a
commercially available FABP
antigen. The minimal detectable concentration was 6 ng/ml and the upper end of the
reportable range was. . .

in the
example above. Alternative or additional markers of myocardial injury include annexin
V, BNP and/or BNP-related peptides, P-enolase, creatine kinase-MB, glycogen
phosphorylase-BB, heart-type fatty
acid binding protein, phosphoglyceric acid
mutase-
MB, and S-100ao.

MMP-9 assay
[01241 Assays for MAV-9 were performed using murine anti-MMP-9 antibodies
generated at Biosite Incorporated, using phage display and recombinant protein
expression techniques. Commercially available NEVIP-9 antigen was used for assay
standardization (Calbiochem-Novabiochem Corporation,. . . on a robotic high-throughput platform
(TECAN Genesis RSP 200/8). The concentration of MMP-9 was quantified by detecting the binding of alkaline phosphatase-conjugated
antibody. All samples were
run in duplicate. The minimal detectable concentration for the assay was 3.0 ng/mL
and the upper end of the. . .

strategies can include, e.g., delivery of antisense compositions
in order to disrupt the synthesis of NWP-9; delivery of receptor-based
therapeutics
(e.g., an antibody composition directed to MMP-9 or a fragment
thereof); and/or
delivery of small molecule thrapeutics (e.g., heparin can decrease MMP-9
synthesis,
tetracycline antibiotics. . .

CLMEN. . . myocardial
injury is selected from the group consisting of annexin V, B-type
natriuretic peptide,
enolase, cardiac troponin I, creatine kinase-MB, glycogen
phosphorylase-BB, heart-
type fatty acid binding
protein, phosphoglyceric acid mutase-MB, and S- 1 00ao.

```
=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or
(daunomycin or daunorubicin)
        188048 ANTI
           185 ANTIS
        188087 ANTI
                 (ANTI OR ANTIS)
         79510 CANCER
         30806 CANCERS
         81924 CANCER
                 (CANCER OR CANCERS)
         12783 ANTI (W) CANCER
         35587 CHEMOTHE?
          4414 ANTHRACYCL?
         18658 DOX?
          5135 ADRIAMYCIN
            17 ADRIAMYCINS
          5142 ADRIAMYCIN
                 (ADRIAMYCIN OR ADRIAMYCINS)
          3555 DAUNOMYCIN
            22 DAUNOMYCINS
          3565 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
          6682 DAUNORUBICIN
            12 DAUNORUBICINS
          6684 DAUNORUBICIN
                 (DAUNORUBICIN OR DAUNORUBICINS)
L18       49281 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR
                ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> d his

     (FILE 'HOME' ENTERED AT 11:23:04 ON 19 DEC 2006)

     FILE 'CAPLUS' ENTERED AT 11:23:26 ON 19 DEC 2006
L1           380 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L2         25686 S DOXORUBICIN OR ADRIAMYCIN
L3             2 S L2 AND L1
L4        748872 S CANCER? OR TUMOR? OR NEOPLAS?
L5            32 S L4 AND L1
L6             8 S L5 NOT PY>2002
L7             2 S L6 AND ANTIBOD?

     FILE 'PCTFULL' ENTERED AT 11:29:43 ON 19 DEC 2006
L8            57 S H-FABP OR (HFABP) OR (H () FABP) OR (HEART-TYPE FATTY ACID BI
L9            41 S L8 AND ANTIBOD?
L10         6166 S L9 AND DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?
```

```
L11           2 S L9 AND (DOXORUCICIN OR DAUNOMYCIN OR ANTHRACYCLIN?)
L12          12 S L9 NOT PY>2002
L13           9 S L12 AND KIT
L14           6 S L8/AB
L15          17 S L8/CLM
L16          19 S L15 OR L14
L17           3 S L16 AND L13
L18       49281 S (ANTI () CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR

=> s l18 and l17
L19           0 L18 AND L17

=> s l19 and l9
L20           0 L19 AND L9

=> s l18 and l9
L21           8 L18 AND L9

=> s l21 not py>2002
        481204 PY>2002
L22           3 L21 NOT PY>2002

=> d ibib 1-3

L22    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2001068851 PCTFULL  ED 20020822
TITLE (ENGLISH):         POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
TITLE (FRENCH):          NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES LES CODANT
INVENTOR(S):             PADIGARU, Muralidhara;
                         VERNET, Corine, A., M.;
                         FERNANDES, Elma;
                         SHIMKETS, Richard, A.;
                         SPADERNA, Steven, K.;
                         MAJUMDER, Kumud;
                         LI, Li
PATENT ASSIGNEE(S):      CURAGEN CORPORATION;
                         PADIGARU, Muralidhara;
                         VERNET, Corine, A., M.;
                         FERNANDES, Elma;
                         SHIMKETS, Richard, A.;
                         SPADERNA, Steven, K.;
                         MAJUMDER, Kumud;
                         LI, Li
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 2001068851         A2 20010920
DESIGNATED STATES
       W:                AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
                         CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
                         IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG
                         MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
                         TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
                         SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
                         CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
                         CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.:       WO 2001-US7735        A  20010312
PRIORITY INFO.:          US 2000-60/188,316       20000310
                         US 2000-60/188,277       20000310
                         US 2000-60/189,139       20000314
                         US 2000-60/189,140       20000314
                         US 2000-60/190,401       20000317
                         US 2000-60/190,231       20000317
```

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000033083 PCTFULL ED 20020515
TITLE (ENGLISH): DIAGNOSIS OF STAGE OR AGGRESSIVENESS OF CANCER
TITLE (FRENCH): DIAGNOSTIC DE LA PHASE D'EVOLUTION OU DE L'AGRESSIVITE DE CANCERS
INVENTOR(S): JETT, Marti;
DAS, Rina;
NEILL, Roger
PATENT ASSIGNEE(S): WRAIR;
JETT, Marti;
DAS, Rina;
NEILL, Roger
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2000033083	A1	20000608

DESIGNATED STATES
W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
APPLICATION INFO.: WO 1999-US28314 A 19991130
PRIORITY INFO.: US 1998-60/110,484 19981201

L22 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 1997035028 PCTFULL ED 20020514
TITLE (ENGLISH): CYTOSTATIN III
TITLE (FRENCH): CYTOSTATINE III
INVENTOR(S): NI, Jian;
YU, Guo-Liang;
GENTZ, Reiner, L.
PATENT ASSIGNEE(S): HUMAN GENOME SCIENCES, INC.;
NI, Jian;
YU, Guo-Liang;
GENTZ, Reiner, L.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9735028	A1	19970925

DESIGNATED STATES
W: AM AU BG BR BY CA CN CZ EE FI GE HU JP KG KP KR KZ LT LV MD MN MX NO NZ PL RO RU SG SI SK TJ TM UA US UZ VN AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE
APPLICATION INFO.: WO 1996-US3697 A 19960319

=> d kwic 2

L22 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN

DETD BACKGROUND OF THE INVENTION
Although screening mammography and the increased use of breast conserving surgery
and adjuvant chemotherapy have improved the quality of life and prolonged survival for women
with breast cancer, additional therapeutic strategies are needed to combat. . .

Modulation of mitogenesis by liver fatty acid binding protein, Cancer Metastasis Rev 13:317-
36, 1994.). In contrast, MDGI (H-FABP) appears only
in normal and not tumor mammary cells
(Grosse R, Boehmer FD, Langen P, Kurtz A, Lehmann W, Mieth M. . . .
types of cytoplasmic fatty acid-binding proteins. Biochim Biophys Acta 1081:1-24, 1991). L-FABP exhibits different lipid binding characteristics from
that of A-FABP or H-FABP. L-FABP transfected into
rat hepatoma cells also mediates cell in-
duction by carcinogenic peroxisome proliferators (Khan SH and Sorof S.: Liver. . .

L-FABP is elevated significantly in metastatic or regenerating liver vs normal liver. This
is in stark contrast to H-FABP, also known as
mammary derived growth inhibitor (MDGI). It is
present only in normal lactating breast, and completely disappears in
mammary. . . performed a similar study (to the eicosanoid generation in
hepatic cells) in MCF-7 cells transfected with a clone of the MDGI (H-FABP) gene or vector
alone. The inventors also have examined these pairs of cells to determine cell cycle pattern
changes related to MDGI. . .

identification of markers that define their degree of differentiation. Cancer Res 57:4111-7,
1997.). Although FABPs are intracellular proteins, H-
FABP has been detected in elevated levels
in plasma and urine of patients suffering from myocardial infarction, (Sohmiya K, Tanaka T,
Tsuji R,. . . III
had 37% reduction and grade IV had no A-FABP expression. A-FABP may act as a growth
inhibitor similar to the MDGI (H-FABP) protein in
breast cancer and loss of A-FABP expression
may serve as a prognostic marker for aggressive bladder cancer.

These results suggests that A-FAIBP and E-FA_BP may act as a tumor suppressors in
prostate cells similar to MDGI (H-FABP) in MCF-7
cells (Huynh H, Alpert L and Pollak M..
fluid but normal prostate cells did not secrete measurable amounts of this protein. In addition, previous studies have shown that a) H
-FABP was secreted into plasma
during severe myocardial infarction and b) E-FABP was decreased in urine in bladder cancer.

The inventors have shown that the pattern of B-, L-, I-FABPs, taken together, along with
decreases in A-, E-, and H-FABPs, are indicative of
the relative agressiveness of the cancer. The
pattern of FABI's provide potential markers to help patients choose a. . .

Furthermore, the normal cell-associated FABPs (E-, A-, and H-
FABPs) were decreased in tumor
cells (3 -II fold). In patient specimens of normal and tumor prostate tissue, these patterns were
repeated, in. . .

sample was used by doing a concentration curve for each sample. These biotin labeled PCR products were quantitated using streptavidin coated antibodies (Streptavidin
has very high affinity for Biotin) which was linked to HRP (Horse Radish Peroxidase) or a
fluorescent tag that was used. . .

.

(Bradford method, Bio Rad, CA) and then ELISA was
performed to evaluate the levels of the various FABI's by using specific antibodies to each of the
different types of FABPs. Antibodies such as heart FABP
antibody and Liver-FABP antibody
obtained from Research Diagnostics, Inc., Pleasant Hill Road, Flanders, NJ 07836 were used in
these tests. However, antibodies for the remaining FABPS can
also be developed and used. The
levels of these proteins were correlated to the stages of. . .

.

4) epidermis or psoriasis-associated (E-
FABP), 5) liver (L-FABP), 6) intestine (1-FABP), and 7) myelin or P2 (P2-FABP). As a group
A-FABP, H-FABP, B-FABP, and E-FABP in humans share
between 50-65% protein sequence
homology and contain a tyrosine near residue 20 that can be. . .

.

MCF-7 ADR cells. This allows the use of this drug when the patient starts showing drug resistance to the commonly used
chemotherapeutic drugs. This drug is
nontoxic to mice when tested for any change in body weight or by necropsy studies. This drug is
also not toxic to human bone marrow cells, which are effected the most during chemotherapy.

.

inhibitors of
eicosanoid metabolism on the growth of breast cancer cells. Inhibitors contemplated are those
currently used in clinical situations such as doxorubicin,
5FU, vinca alkaloids, adriamycin as
well as lipoxygenase inhibitors. The HPA drug can be given
simultaneously with or can be given
followed by exposing the cancerous. . . to block the growth of the cancerous cells and change the FABP profile to a normal cell FABP profile. Subsequent
27
applications of chemotherapeutic agents or inhibitor can be
given in a lower amount than
previous applications.

.

representing unique regions of each specific FABP. We will synthesize these peptides,
attach them to a carrier molecule and generate specific
antibodies for each of FABPs. These
30
antibodies are crucial for use in development of ELISA
procedures to detect each of the specific
FABI's in body fluids and, perhaps,. . .

CLMEN. . . 8 The method of claim 4, wherein said detecting comprises measuring the amount fatty
acid binding proteins in the sample with antibodies and
determining type of fatty acid
binding protein in the sample by ELISA.

.

9 The method of claim 5, wherein said detecting comprises measuring the amount fatty

acid binding proteins in the sample with antibodies and
determining type of fatty acid
binding protein in the sample by ELISA.

10 The method of claim 8, wherein said antibodies are specific
to at least one protein
selected from the group consisting of Liver-FABP, Intestinal-FABP,
Adipose-FABP,
CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

11 The method of claim 9, wherein said antibodies are specific
to at least one protein
selected from the group consisting of Liver-FABP, Intestinal-FABP,
Adipose-FABP,
CRAB-1, Brain-FABP, Epidermal-FABP and Muscle/Heart-FABP.

. . .
of-
a) detecting the amount of at least one fatty acid binding protein
present in a sample
of mammalian body fluid with antibodies specific to said fatty
acid binding
protein;
b) determining the difference in the amount of the at least one fatty
acid binding
protein. . .

. . .
the
steps of-
a) detecting the amount of at least one fatty acid binding protein
present in a sample
of mammalian tissue with antibodies specific to said fatty
acid binding protein;
39
b) detennining the difference in the amount of the at least one fatty
acid. . .

. . .
cell
FABP profile to a normal cell FABP profile; and
b) exposing the cancer cells to a first predetermined amount of a
chemotherapeutic
agent or cancer inhibitor sufficient to block the growth of the cells.

21 The method of claim 19, wherein said inhibitor is doxorubicin
, 5FU, vinca alkaloids or
lipoxygenase inhibitors.

26 The method of inhibiting growth of cancer cells of claim 19, further
comprising exposing the
cancer cells to a chemotherapeutic agent or inhibitor a second
time in a second lower amount
than said first predetermined amount.

. . .
of breast or. prostate cancer cells of claim 19, wherein the
method of inhibiting directed to breast cells and the known
chemotherapeutic agent or drug
is one of 5-flourouracil or adriamycin.

=> file dissab

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.07	92.31

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE 0.00 -0.75

FILE 'DISSABS' ENTERED AT 11:39:16 ON 19 DEC 2006

FILE COVERS 1861 TO 27 NOV 2006 (20061127/ED)

=> s h-FABP or (HFABP) or (H () FABP) or (heart-type fatty acid binding protein) or (heart type factty acid () binding protein)

```
         59809 H
            95 FABP
            29 FABPS
           102 FABP
                 (FABP OR FABPS)
            13 H-FABP
                 (H(W)FABP)
             1 HFABP
         59809 H
            95 FABP
            29 FABPS
           102 FABP
                 (FABP OR FABPS)
            13 H (W) FABP
         19262 HEART
          1651 HEARTS
         20021 HEART
                 (HEART OR HEARTS)
        138410 TYPE
         97741 TYPES
        211295 TYPE
                 (TYPE OR TYPES)
          7556 FATTY
             1 FATTIES
          7557 FATTY
                 (FATTY OR FATTIES)
         68494 ACID
         24901 ACIDS
         80503 ACID
                 (ACID OR ACIDS)
         49720 BINDING
           166 BINDINGS
         49793 BINDING
                 (BINDING OR BINDINGS)
         80601 PROTEIN
         44527 PROTEINS
         93270 PROTEIN
                 (PROTEIN OR PROTEINS)
             3 HEART-TYPE FATTY ACID BINDING PROTEIN
                 (HEART(W)TYPE(W)FATTY(W)ACID(W)BINDING(W)PROTEIN)
         19262 HEART
          1651 HEARTS
         20021 HEART
                 (HEART OR HEARTS)
        138410 TYPE
         97741 TYPES
        211295 TYPE
```

```
                (TYPE OR TYPES)
             0 FACTTY
         68494 ACID
         24901 ACIDS
         80503 ACID
                (ACID OR ACIDS)
             0 HEART TYPE FACTTY ACID
                (HEART(W)TYPE(W)FACTTY(W)ACID)
         49720 BINDING
           166 BINDINGS
         49793 BINDING
                (BINDING OR BINDINGS)
         80601 PROTEIN
         44527 PROTEINS
         93270 PROTEIN
                (PROTEIN OR PROTEINS)
          7721 BINDING PROTEIN
                (BINDING(W)PROTEIN)
             0 HEART TYPE FACTTY ACID (W) BINDING PROTEIN
L23         15 H-FABP OR (HFABP) OR (H (W) FABP) OR (HEART-TYPE FATTY ACID
               BINDING PROTEIN) OR (HEART TYPE FACTTY ACID (W) BINDING PROTEIN)

=> s l23 and antibod?
         19910 ANTIBOD?
L24          3 L23 AND ANTIBOD?

=> d ibib 1-3

L24  ANSWER 1 OF 3  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   2001:30986  DISSABS   Order Number: AAI9991903
TITLE:              Mechanisms of fatty acid transport and uptake by adipocyte
                    fatty acid-binding protein
AUTHOR:             Liou, Heng-Ling [Ph.D.]; Storch, Judith [adviser]
CORPORATE SOURCE:   Rutgers The State University of New Jersey - New Brunswick
                    (0190)
SOURCE:             Dissertation Abstracts International, (2000) Vol. 61, No.
                    10B, p. 5242. Order No.: AAI9991903. 251 pages.
                    ISBN: 0-599-99576-9.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English

L24  ANSWER 2 OF 3  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   97:77250  DISSABS   Order Number: AAR9800797
TITLE:              STRUCTURE, FUNCTION AND DISTRIBUTION OF LIPID BINDING
                    PROTEINS IN MOUSE BRAIN (HEART FATTY ACID BINDING PROTEIN,
                    AGING)
AUTHOR:             PU, LIXIA [PH.D.]; SCHROEDER, FRIEDHELM [advisor]
CORPORATE SOURCE:   TEXAS A&M UNIVERSITY (0803)
SOURCE:             Dissertation Abstracts International, (1997) Vol. 58, No.
                    7B, p. 3597. Order No.: AAR9800797. 147 pages.
DOCUMENT TYPE:      Dissertation
FILE SEGMENT:       DAI
LANGUAGE:           English
ENTRY DATE:         Entered STN: 19971124
                    Last Updated on STN: 19971124

L24  ANSWER 3 OF 3  DISSABS COPYRIGHT (C) 2006 ProQuest Information and
     Learning Company; All Rights Reserved on STN
ACCESSION NUMBER:   94:22128  DISSABS   Order Number: AARC349190 (not available
                    for sale by UMI)
TITLE:              HETEROLOGOUS EXPRESSION OF THE BOVINE CARDIAC FATTY
                    ACID-BINDING PROTEIN (H-FABP) IN THE
```

YEAST YARROWIA LIPOLYTICA: BIOCHEMICAL AND PHYSIOLOGICAL STUDIES
HETEROLOGE EXPRESSION DES FETTSAEURE-BINDENDEN PROTEINS AUS RINDERHERZ (H-FABP) IN DER HEFE
YARROWIA LIPOLYTICA: BIOCHEMISCHE UND PHYSIOLOGISCHE UNTERSUCHUNGEN

AUTHOR: BAUER, RONALD EDUARD [DR.TECHN.]
CORPORATE SOURCE: TECHNISCHE UNIVERSITAET GRAZ (AUSTRIA) (5800)
SOURCE: Dissertation Abstracts International, (1993) Vol. 55, No. 2C, p. 449. Order No.: AARC349190 (not available for sale by UMI). UNIVERSITY LIBRARY, TECHNISCHE UNIVERSITAT GRAZ, TECHNIKERSTRASSE 4, A-8010 GRAZ, AUSTRIA.
DOCUMENT TYPE: Dissertation
FILE SEGMENT: DAI
LANGUAGE: German
ENTRY DATE: Entered STN: 19940607
Last Updated on STN: 19940607

```
=> s (anti () cancer) or (chemothe?) or (anthracycl?) or (dox? or adriamycin) or
(daunomycin or daunorubicin)
         27176 ANTI
            10 ANTIS
         27182 ANTI
                 (ANTI OR ANTIS)
         15632 CANCER
          2379 CANCERS
         16412 CANCER
                 (CANCER OR CANCERS)
           488 ANTI (W) CANCER
          2780 CHEMOTHE?
           247 ANTHRACYCL?
           825 DOX?
           257 ADRIAMYCIN
            92 DAUNOMYCIN
             1 DAUNOMYCINS
            92 DAUNOMYCIN
                 (DAUNOMYCIN OR DAUNOMYCINS)
            78 DAUNORUBICIN
L25        4221 (ANTI (W) CANCER) OR (CHEMOTHE?) OR (ANTHRACYCL?) OR (DOX? OR
               ADRIAMYCIN) OR (DAUNOMYCIN OR DAUNORUBICIN)

=> s l24 and l25
L26           0 L24 AND L25

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               4.57      96.88

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -0.75
```

STN INTERNATIONAL LOGOFF AT 11:40:15 ON 19 DEC 2006